general news

South Korea allows emergency use of remdesivir for COVID-19 patients

South Korea allows emergency use of remdesivir for COVID-19 patients
South Korea allows emergency use of remdesivir for COVID-19 patients

South Korea has recently announced that it has approved the emergency use of remdesivir, developed by Gilead Sciences, in order to treat COVID-19 after a panel of government officials had cited some positive results the drug showed in several other nations.

Remdesivir is usually administered in hospitals and is the very first drug to depict improvement in patients suffering from COVID-19 in various formal clinical trials. The Ministry For Food and Drug Safety of South Korea said that remdesivir is capable of reducing the amount of coronavirus present in the body. It could enable the condition of the patient to improve at a faster rate.

Gilead had stated that the drug had offered the most decent benefits in patients suffering from moderate coronavirus by providing them with a five-day course of treatment, while people who received their medicines for 10 days had not given suitable results.

As per the guidelines that have been announced by the Ministry for Food and Drug Safety of South Korea, the doctors shall be allowed to give a dose of remdesivir every day with about 5 doses in total for patients suffering from moderate symptoms and 10 doses for the patients whose symptoms have been severe and also need oxygen support.

The Japanese health authorities have also given their approval for the drug that had been manufactured to fight Ebola at one time.

The ministry has also said that it will be cooperating with Korea Centers for Disease Control and Prevention, Gilead, as well as several other ministries to be able to quickly import the drug.

According to sources familiar with the matter, the U.S. Food and Drug Administration had given the permission for emergency use authorization in the previous month after citing results based on a study by the US government, which said that drug had lowered the number of hospitalization stays by about 31% or even close to four days in comparison with placebo.


Source Credit-

About the author

Omkar Patwardhan

Omkar Patwardhan started his professional career in the hospitality industry. Having nurtured a deep-sated passion for words however, he found his way into content writing and now pens down articles for and a few other websites, spanning the sectors of business, finance, and technology./